source
- Roivant's brepocitinib shows strong Phase 3 results, paving way for uveitis indicationRoivant subsidiary Priovant Therapeutics announced positive Phase 3 data for its anti‑inflammatory drug brepocitinib in patients with non‑infectious uveitis, an eye disease that can cause blindness…
- Hologic acquires Spain’s Reveal Genomics to expand breast cancer genomic testingHologic, a medical‑technology company, announced it will acquire precision‑oncology firm Reveal Genomics, based in Spain. Reveal Genomics develops advanced genomic diagnostic tests, notably the HE…